Summary Pleural effusion samples were obtained from 55 patients with malignant disease, including patients with primary lung cancers and those with a variety of other tumours metastatic to the pleura. The effusions were assayed for the presence of hepatocyte growth factor/scatter factor (HGF/SF), by both ELISA and bioassay. The presence of malignant cells in the effusions was also assessed. Detectable amounts of the factor, as judged by both criteria, were found in over 90% of all the effusions, including those from patients with a wide variety of carcinomas and also lymphomas. A wide range of HGF/SF levels were found for all tumour classes, some effusions containing high levels above 4 ng ml-. It is concluded that tumours within the pleura and adjacent lung tissue are usually exposed to biologically significant levels of HGF/SF.
There is now a large body of evidence demonstrating that a wide variety of cytokines and growth factors modulate the growth and dissemination of many tumour cell types. Among these are a number of growth factors that also have marked effects on cell motility and on cell adhesional properties (reviews Stoker and Gherardi, 1991; Warn, 1994) . Scatter factor was the first such factor to be identified as capable of rupturing cell-cell adhesions and thus dissociating or scattering epithelial cell colonies in culture (Stoker and Perryman, 1985; Stoker et al., 1987) . Sequence analysis (Weidner et al., 1991) demonstrated scatter factor to be the same molecule as hepatocyte growth factor, a strong growth promoter for many epithelial cell types and also endothelial cells (reviews Matsumoto et al., 1993; Tsubouchi et al., 1993) . The molecule is now commonly referred to as hepatocyte growth factor/scatter factor (HGF/SF). HGF/SF is a heterodimeric protein with an Mr of approximately 90 000 Da consisting of a 62 kDa A-chain and a 34/32 kDa B-chain (review Gherardi et al., 1993) . It scatters a wide variety of normal and tumour-derived epithelial cell lines and also stimulates the migration of tumour cell lines into collagen gels, thus enhancing their invasive properties in vitro (Weidner et al., 1990) . The receptor for HGF/SF has been identified to be the product of the c-met proto-oncogene (Bottaro et al., 1991; Naldini et al., 1991) , a transmembrane glycoprotein with a tyrosine kinase domain forming a key part of the internal structure. A wide range of tumour types have been found to have raised levels of c-met (Di Renzo et al., 1991; Prat et al., 1991) . Of these tumours, the highest levels were seen in human thyroid cancers, where there was frequently more than a 100-fold amplification compared with normal thyroid tissue.
The above properties suggest that HGF/SF may be involved in cancer development. In a previous study (Kenworthy et al., 1992) we demonstrated that HGF/SF could be identified in a significant proportion of a small number of pleural effusion fluids obtained from patients with metastatic spread to the pleura. Here we extend this work to a much larger group of patients with primary or secondary tumours of a variety of types, including lymphomas.
Materials and methods
Collection and processing of samples Pleural effusion fluid was obtained by aspiration and the cells were removed by centrifugation for subsequent cytopathological investigation. Between 5 and 20 ml of fluid was routinely obtained, aliquotted and frozen until assayed. For each patient, the records of the Department of Histopathology/Cytopathology were examined and, when appropriate, the case notes were reviewed.
ELISA Pleural effusion samples were tested for the presence of HGF/ SF using the enzyme-linked immunosorbent assay (ELISA) developed by . This is a sandwich method consisting of three steps, originally developed for the detection of HGF/SF in the serum of patients with acute liver failure. It has a detection limit of approximately 0.2 ng ml-' and is highly specific for human HGF/SF.
Scattering bio-assay This was carried out following the method of Stoker and Perryman (1985 aSamples that were negative on the scattering bioassay.
primary lung carcinomas, malignant pleural mesotheliomas, metastatic carcinomas, malignant lymphomas and miscellaneous neoplasms. It is clear that, judged by ELISA level, all but three samples (64 out of 67) contained levels of HGF/SF above that considered to be background (approximately 0.2 ng ml-1). Turning first to primary lung carcinomas, samples were obtained from patients with adenocarcinoma, squamous cell carcinoma, small-cell anaplastic carcinoma and a single carcinoma showing mixed differentiation. The median HGF/ SF ELISA for all primary lung carcinomas was found to be 0.49 ng ml-'. (Table I ). Among the samples from the squamous carcinoma patients, one (the last of four obtained from the same patient) was much higher at 6.76 ng ml-' than all the rest. Another sample from a different patient had an HGF/SF titre of 4.15 ng ml-'. The samples for the lung adenocarcinoma patients did not contain any high samples but one was only just above the baseline and proved negative on the scattering bio-assay (see below). One might expect higher HGF/SF levels to be present in samples in which malignant cells were identified but among the samples we assayed this was not so. All the effusions from patients with adenocarcinoma of the lung contained malignant cells but only in two out of five patients with squamous cell carcinomas were malignant cells found in an effusion. Among the squamous cell carcinoma samples the first high ELISA sample (6.76 ng ml-') did not contain malignant cells but the second high sample (4.15 ng ml-1) did. Four samples were obtained from four patients with small-cell anaplastic carcinoma with a median HGF/SF level of 0.58 ng ml-'. Of these samples malignant cells were found in only one. Pleural effusions were also taken from three patients with malignant mesothelioma and, as would be expected, malignant cells were found in all samples. All the samples were positive for HGF/SF; the median (2.05 ng ml-1) was the highest for any group of tumours.
( Table I) .
The next category (other metastatic carcinomas) included adenocarcinomas from a variety of known origins that had metastasised to the pleura (Table II) . Counting all the samples from patients with non-bronchial adenocarcinomas, a median ELISA of 1.12 ng ml-' was found. Among these samples the most numerous main primary sites were breast, prostate and colon. All the breast carcinoma samples were found to contain significant levels of HGF/SF (median 1.26 ng ml-') but none was particularly high, the highest level found being 2.42 ng ml-'. All the patients had malignant cells in their effusions. The median (1.07 ng ml-') and range of the samples from patients with prostatic adenocarcinoma were rather similar while the few (three) samples from patients with colonic adenocarcinoma had a rather lower median (0.64 ng ml-'). One of the pleural effusions from a patient with prostatic adenocarcinoma proved to have a HGF/SF below baseline (0.18 ng ml-1) but was just positive on the scattering bioassay. Malignant HGF/SF in pleural effusions G Eagles et a! The last, miscellaneous, group includes single samples from several different types of malignant disease. There were effusion samples from two other carcinomas, one of unknown origin and the other from a patient with a squamous cell carcinoma of the oesophagus. The latter had a very high level of HGF/SF (9.70 ng ml-'). Cancer cells were not seen in this sample but, because of the proximity of the tumour to the pleura, involvement was very likely. The effusion from the patient with acute myeloblastic leukaemia had a very high HGF/SF ELISA of 1 1.0 ng ml-1, the highest of all the samples seen. No malignant cells were found in this sample. However, the patient was suffering from a severe chest infection due to immunocompromise. The last class of malignant tumour in our samples was represented by pleural effusion fluid from one patient with a mediastinal embryonal rhabdomyosarcoma. Here an ELISA of 7.46 ng ml-1 was recorded, the second highest for all the cancer patients. Malignant cells were not seen in the effusion fluid of this patient but extensive involvement of the pleura was observed upon thoracoscopy.
A major question in a study such as this is how well HGF/ SF levels measured immunologically correspond to biological activity. To answer this, 90 effusion samples from the cancer patients (and also some other non-cancer patients) were tested on the scattering bioassay. The data are presented as Table III . All the ELISA samples, except one, below a baseline of 0.2 ng ml-' corresponded to clear-cut negatives on the scattering bioassay. The single positive (ELISA 0.18 ng ml-') corresponded to an end point at the lowest dilution tested. Three samples with an ELISA slightly above 0.2 ng ml-' showed no scattering (0.28, 0.25 and 0.22 ng ml-'). Two others were positive (0.28 and 0.27 ng ml-') at the lowest dilution, so for pleural effusion fluids an ELISA baseline of about 0.25 ng ml-' corresponded very well with the detection of scattering activity at the limit. A Rygaard et al. (1993a) found that only 2 out of 25 small-cell lung carcinoma (SCLC) lines contained HGF/SF transcripts, and of these only one also expressed cmet. However, a number of SCLC cell lines are scattered by HGF/SF and thus can respond to the factor (Rygaard et al., 1993b) . At present very few epithelial cell lines have been found to secrete HGF/SF and the general conclusion is that the factor is much more usually a paracrine effector (Gherardi et al., 1993; Sonnenberg et al., 1993) .
A second possibility is that the tumour stroma may secrete HGF/SF. A number of human lung fibroblast lines of various origins secrete HGF/SF in culture (see Gherardi et al., 1993) A third possible origin of the HGF/SF is that it is derived G Eagles et al 380 from the lung as part of a host tissue response to the growing tumour. There is experimental evidence that the induction of lung damage is rapidly followed by HGF/SF synthesis within the lung. Yanagita et al. (1993) injected hydrochloride into the tracheas of rats and found a rapid appearance of HGF/ SF transcripts followed by an increase in HGF/SF activity. It seems likely that HGF/SF is secreted in response to damage and disease. This could well occur during tumorigenesis in the lung. The final potential origin is that some of the HGF/SF found in the effusions is secreted into the blood by other organs, in particular the liver. The mechanism for this would be that the secreted HGF/SF enters the general circulation and escapes into the pleural fluid via capillary damage due to the tumour, or localised inflammation. At present there is no evidence that this occurs, although it cannot be excluded. Recent experimental evidence has demonstrated that the reverse can occur. For rats it has been found that partial hepatectomy is followed by a rapid increase in blood HGF/ SF levels due to its synthesis by other tissues, including the lung (Kinoshita et al., 1991) . At present we cannot distinguish the potential contributions from the different possible sources of HGF/SF described above; it will be necessary to directly identify which cells within the lungs secrete HGF/SF.
So far only one study has been made of the location of HGF/SF within the lungs. This was of patients with primary lung tumours and done using immunocytochemistry of fixed materal (Yoshinaga et al., 1993) . Much of the HGF/SF was found to be associated with extracellular matrix material, particularly the basement membranes of tumour cells and also of the adjacent bronchial epithelium. These authors proposed that much of the observed HGF/SF was bound to heparin. Our results demonstrate that significant amounts of soluble HGF/SF are present in the tumour environment of the lung, at least in cases in which the pleura is involved, and probably more widely.
Comparison of HGF/SF levels associated with different tumour types The levels of HGF/SF pleural effusion fluids from patients with various types of malignant disease varied widely. A trivial explanation could be that the amount of HGF/SF present simply reflected the protein concentration. However, measurement of the latter in samples showed no such correlation. Samples with the same protein concentration were found to have up to a 10-fold difference in HGF/SF concentrations.
The most interesting comparison between tumour classes was that between the median HGF/SF ELISA value of primary lung adenocarcinomas and that of all metastatic adenocarcinomas. Although the sample sizes were small, the range for the lung adenocarcinomas was much less than the much bigger range for all metastatic adenocarcinomas, including two high values above 4ngml-. It may be that metastic adenocarcinomas can induce higher levels of HGF/ SF within the pleural effusions. Taniguchi et al. (1994) have reported a significant difference of mean HGF/SF serum levels from primary breast cancer patients as compared with samples from patients with recurrent breast cancer. They suggested that this increase was associated with tumour progression, particularly when metastases to the liver occurred.
A comparison of the different classes of primary lung tumours showed quite large differences but these were not statistically significant, possibly because of the large variances found. Indeed the large variation in HGF/SF levels was a consistent feature seen for all the types of tumours recorded. (Mooi and Addis, 1990 Gohda et al., 1988) . Furthermore, we have determined that scattering is first stimulated in culture at around 0.25 ng ml-'. Thus the levels of HGF/SF found in the pleural effusion fluids are clearly similar to the amounts sufficient to cause mitogenesis and scattering in vitro. A number of in vitro and in vivo studies have shown that cmet is frequently expressed in both non-small cell (Tsao et al., 1993) and small-cell carcinoma cell lines (Rygaard et al., 1993a) and in a range of tumour types including lung carcinomas (di Renzo et al., 1991; Prat et al., 1991) . Therefore, if, as we have demonstrated in pleural effusions, free HGF/SF is present within the lung around any tumour cells carrying c-met, then the cells will probably respond to it. In consequence, the presence of c-met on the surfaces of lung tumours may prove to be important for future cancer therapy strategies. However, caution is required before drawing any general conclusions relating c-met activation to enhanced mitosis and/or scattering. HGF/SF also induces tubulogenesis of MDCK cells when grown in suspension within collagen gels (Montesano et al., 1991) . This is a differentiation event, but one linked with mitogenesis. HGF/SF can also inhibit rather than enhance the growth rates of certain cell lines in culture (Higashio et al., 1990; Tajima et al., 1991; Jiang et al., 1993) and this list now includes SCLC lines (Rygaard et al., 1993b) . At high concentrations (above 5 ng ml-') stimulation of the growth of human biliary cells passes into inhibition (Strain et al., 1991) . Therefore HGF/SF is a bidirectional growth regulator and not just a mitogen. In spite of these qualifications it is clear that tumour cells growing within the pleura and adjacent lung tissue may be exposed to varying but biologically significant levels of HGF/SF. Study now must be made of which cell types within the lung secrete HGF/SF and the varying ways in which tumour cells, particularly those of the lung and pleura, may respond to it.
